Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial

JAMA Oncology

Volumn 1, Issue 5, 2015, Pages 643-651

  Pardanani, Animesh ^a   Harrison, Claire ^b   Cortes, Jorge E ^c   Cervantes, Francisco ^d   Mesa, Ruben A ^e   Milligan, Donald ^f   Masszi, Tamás ^g   Mishchenko, Elena ^h   Jourdan, Eric ⁱ   Vannucchi, Alessandro M ^j   Drummond, Mark W ^k   Jurgutis, Mindaugas ^l   Kuliczkowski, Kazimierz ^m   Gheorghita, Emanuil ⁿ   Passamonti, Francesco ^o   Neumann, Frank ^p   Patki, Abhay ^p   Gao, Guozhi ^p   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF BARCELONA   (Spain)

^e MAYO CLINIC   (United States)

^f BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^g Szent Laszlo Hospital   (Hungary)

^h BNAI ZION MEDICAL CENTER   (Israel)

ⁱ University of Florence ^*  (France)

^j UNIVERSITY OF FLORENCE   (Italy)

^k BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^l Klaipeda Seamen's Hospital   (Lithuania)

^m WROCLAW MEDICAL UNIVERSITY   (Poland)

ⁿ Romania Aleea L cr mioarelor   (Romania)

^o OSPEDALE DI CIRCOLO   (Italy)

^p NONE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FEDRATINIB; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; PROTEIN KINASE INHIBITOR; PYRROLIDINE DERIVATIVE; SULFONAMIDE;

ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; MULTICENTER STUDY; MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; ORGAN SIZE; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PRIMARY MYELOFIBROSIS; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; SPLEEN; SPLENOMEGALY; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; JANUS KINASE 2; MAGNETIC RESONANCE IMAGING; MUTATION; ORGAN SIZE; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; PYRROLIDINES; SPLEEN; SPLENOMEGALY; SULFONAMIDES; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84964694744     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.1590     Document Type: Article

References (26)

1. Tefferi A. Myelofibrosis with myeloidmetaplasia. N Engl J Med. 2000;342(17):1255-1265.
2. Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primarymyelofibrosis: the Mayo Clinic experience. Mayo Clin Proc. 2012;87(1):25-33.
3. Jatiani SS, Baker SJ, Silverman LR, Reddy EP. Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes Cancer. 2010;1(10):979-993.
4. Tefferi A. Novel mutations and their functional and clinical relevance inmyeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24(6):1128-1138.
5. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations inmyeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369 (25):2391-2405.
6. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013; 369(25):2379-2390.
7. Kroeger N, Holler E, Kobbe G, et al. Dose-reduced conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis: results from a multicenter prospective trial of the chronic leukemia working party of the European Group for Blood and Marrow Transplantation (BMT). Blood. 2007;110(suppl): abstr 683.
8. Tefferi A. Primarymyelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013;88(2):141-150.
9. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy formyelofibrosis. N Engl J Med. 2012;366 (9):787-798.
10. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib formyelofibrosis. N Engl J Med. 2012; 366(9):799-807.
11. Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib in patientswith myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013;98(12):1865-1871.
12. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, inmyelofibrosis. J Clin Oncol. 2011;29(7):789-796.
13. Talpaz M, Jamieson C, Gabrail N, et al. Modulation of plasma cytokines and its association with clinical response to treatment with the JAK2-selective inhibitor SAR302503 in myelofibrosis (MF). J Clin Oncol. 2013;31(suppl 15):abstr 7110.
14. Gotlib J, Pardanani A, Jamieson C, et al. Long-term follow up of a phase 1/2 study of SAR302503, an oral JAK2 selective inhibitor, in patients withmyelofibrosis (MF). Haematologica. 2012;97(s1):145.
15. Zhou T, Georgeon S, Moser R, Moore DJ, Caflisch A, Hantschel O. Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348). Leukemia. 2014;28(2):404-407.
16. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification ofmyeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
17. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primarymyelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.
18. Barosi G, Mesa RA, Thiele J, et al; International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22(2):437-438.
19. Mesa RA, Kantarjian H, Tefferi A, et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer. 2011;117(21): 4869-4877.
20. Torvik A, Lindboe CF, Rogde S. Brain lesions in alcoholics: a neuropathological study with clinical correlations. J Neurol Sci. 1982;56(2-3):233-248.
21. Wu J, Zhang L, Vaze A, Lin S, Juhaeri J. Risk of Wernicke's encephalopathy and cardiac disorders in patients with myeloproliferative neoplasm. Cancer Epidemiol. 2015;39(2):242-249.
22. Sechi G, Serra A. Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol. 2007;6(5):442-455.
23. Zhang Q, Zhang Y, Diamond S, et al. The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy. Drug Metab Dispos. 2014;42(10):1656-1662.
24. Quintás-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment ofmyeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011;10(2):127-140.
25. Plimack ER, Lorusso PM, McCoon P, et al. AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors. Oncologist. 2013;18(7):819-820.
26. Abdelrahman RA, Begna KH, Al-Kali A, et al. Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients withmyelofibrosis. Br J Haematol. 2015;169(1):77-80.